Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Oncology Inc (CTOR)

Citius Oncology Inc (CTOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Citius Oncology Inc 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 USA

www.citiusonc.com P: 908-967-6677

Sector:

Medical

Description:

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. Citius Oncology Inc., formerly known as TenX Keane Acquisition, is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 93,526
Enterprise Value, $K 97,916
Shares Outstanding, K 83,513
Annual Sales, $ 0 K
Annual Net Income, $ -21,150 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,370 K
EBIT, $ -37,710 K
EBITDA, $ -37,710 K
60-Month Beta 2.98
% of Insider Shareholders 6.66%
% of Institutional Shareholders 70.52%
Float, K 77,951
% Float 93.34%
Short Volume Ratio 0.60

Growth:

1-Year Return -24.31%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.08 on 08/12/25
Next Earnings Date 05/09/25
Earnings Per Share ttm -0.28
EPS Growth vs. Prev Qtr 27.27%
EPS Growth vs. Prev Year -300.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CTOR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -51.93%
Return-on-Assets % -22.16%
Profit Margin % 0.00%
Debt/Equity 0.35
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.69
Book Value/Share 0.41
Interest Coverage -0.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar